![]() |
|
|
Vol. 288, Issue 3, 951-959, March 1999
Department of Pharmaceutical Sciences, Wayne State University, Detroit, Michigan
| |
Abstract |
|---|
|
|
|---|
Differences in the incidence of adverse drug reactions to trimethoprim-sulfamethoxazole and dapsone may result from differences in the formation, disposition, toxicity, and/or detoxification of their hydroxylamine metabolites. In this study, we examine whether differences in the biochemical processing of sulfamethoxazole hydroxylamine (SMX-NOH) and dapsone hydroxylamine (DDS-NOH) by erythrocytes [red blood cells (RBCs)] contribute to this differential incidence. The methemoglobin (MetHgb)-forming capacity of both metabolites was compared after a 60-min incubation with washed RBCs from four healthy human volunteers. DDS-NOH was significantly more potent (P = .004) but equally efficacious with SMX-NOH in its ability to form MetHgb. The elimination of potential differences in disposition by lysing RBCs did not change the MetHgb-forming potency of either hydroxylamine. At pharmacologically relevant concentrations, greater reduction to the parent amine occurred with DDS-NOH. Maintenance of MetHgb-forming potency was dependent on recycling with glutathione, but no difference in cycling efficiency was observed between DDS-NOH and SMX-NOH. In contrast, the pharmacodynamics of hydroxylamine-induced MetHgb formation were not changed by pretreatment with the glucose 6-phosphate dehydrogenase inhibitor epiandrosterone or by compounds that alter normal antioxidant enzyme activity. Methylene blue, which stimulates NADPH-dependent MetHgb reductase activity, decreased MetHgb levels but did not alter the differential potency of these hydroxylamines. DDS-NOH was also significantly more potent when incubated with purified human hemoglobin A0. Collectively, these data suggest that the inherently greater reactivity of DDS-NOH with hemoglobin, the greater conversion of DDS-NOH to its parent amine, and potential differences in disposition of hydroxylamine metabolites may contribute to the preferential development of dapsone-induced hemotoxicity and sulfamethoxazole-induced hypersensitivity reactions.
| |
Introduction |
|---|
|
|
|---|
Trimethoprim-sulfamethoxazole
and dapsone are viewed by many clinicians as the primary and secondary
choice, respectively, for prophylaxis and treatment of
Pneumocystis carinii pneumonia in AIDS patients (Gallant et
al., 1994
). An association with a high incidence of adverse drug
reactions (ADRs), however, hampers their clinical usefulness.
Limitations in the use of trimethoprim-sulfamethoxazole can be largely
attributed to the development of dose-independent hypersensitivity
reactions that generally manifest as fever and cutaneous reactions
within 7 to 14 days of initiating treatment (Rieder et al., 1989
; Cribb
et al., 1996a
). In certain patients, more severe systemic reactions
involving liver, kidney, bone marrow, and heart have also been observed
(Rieder et al., 1989
; Cribb et al., 1996a
). Although dapsone causes
similar hypersensitivity reactions, dose-limiting hematologic toxicity
characterized by methemoglobinemia and hemolysis also occurs at an
equal or greater frequency in patients with AIDS (Lee et al., 1989
;
Medina et al., 1990
; Torres et al., 1993
; Beumont et al., 1996
) and is
the most common dapsone-induced ADR in individuals not infected with
human immunodeficiency virus (Jollow et al., 1995
).
Experimental data support the hypothesis that bioactivation is critical
in the pathogenesis of dapsone- and sulfamethoxazole-induced ADRs.
Oxidative metabolism produces reactive hydroxylamine metabolites that
are cytotoxic and capable of binding cellular macromolecules (Rieder et
al., 1988
; Coleman et al., 1989
; Cribb et al., 1991
; Cribb et al.,
1996b
). In the case of sulfamethoxazole, sulfamethoxazole hydroxylamine
(SMX-NOH)-induced in vitro cytotoxicity toward peripheral blood
mononuclear cells correlates with the development of
sulfonamide-induced hypersensitivity reactions (Rieder et al., 1989
;
Carr et al., 1993
). Studies with dapsone similarly link hydroxylamine
formation to the development of hemotoxicity (Hjelm and Deverdier,
1965
; Glader and Conrad, 1973
; Grossman and Jollow, 1988
) and
idiosyncratic blood dyscrasias (Coleman et al., 1994b
; Ahmadi et al.,
1996
). Taken together, this evidence suggests that hydroxylamine
metabolites mediate ADR development, possibly through spontaneous
autoxidation to more reactive nitroso byproducts (Cribb et al., 1991
).
Although a number of other factors are likely to play an important
role, this relationship between hydroxylamine toxicity and ADR
development also suggests that arylamines giving rise to the largest
amount of hydroxylamine should yield the highest incidence of adverse effects.
Comparison of reports on the in vivo metabolism of these arylamines
indicate that 20 to 35% of dapsone is excreted as dapsone hydroxylamine (DDS-NOH) and an unknown fraction is excreted as monoacetyldapsone hydroxylamine (MADDS-NOH) (Coleman et al., 1990
). In
contrast, less than 3% of sulfamethoxazole is excreted as SMX-NOH (Cribb and Spielberg, 1992
; van der Ven et al., 1994
). Taking into
account differences in normal dosages administered for pneumocystis prophylaxis/treatment, comparable levels of hydroxylamine might be
observed, although hydroxylamine metabolite levels of dapsone may still
be higher, depending on the formation of MADDS-NOH. Importantly,
however, dapsone therapy causes a significantly lower incidence of
hypersensitivity reactions than trimethoprim-sulfamethoxazole (Lee et
al., 1989
; Medina et al., 1990
; Pertel and Hirschtick, 1994
). One study
in particular reported a 57% incidence of hypersensitivity to
trimethoprim-sulfamethoxazole but only a 30% incidence to
trimethoprim-dapsone (Medina et al., 1990
). Regardless of whether
sulfamethoxazole forms a comparable or lower amount of hydroxylamine,
it produces a significantly higher frequency of idiosyncratic ADRs.
One mechanism that may contribute to this differential sensitivity
between sulfamethoxazole and dapsone is a difference in the
detoxification of reactive metabolites. Erythrocytes have been shown to
be an important site for detoxification of DDS-NOH (Coleman and
Jacobus, 1993
; Tingle and Park, 1993
) but not for other hydroxylamines
(Tingle and Park, 1993
). Thus, differential detoxification of
hydroxylamine metabolites by erythrocytes [red blood cells (RBCs)]
might contribute to the differential incidence of hypersensitivity
reactions between dapsone and sulfamethoxazole. The studies described
herein were designed to further probe the biochemical processing and
detoxification of hydroxylamine metabolites by human RBCs.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Hydroxylamine metabolites of dapsone and
sulfamethoxazole were synthesized as described previously (Rieder et
al., 1988
; Vage et al., 1994
). Product identity was confirmed for each
hydroxylamine by NMR and IR spectroscopy. Purity, determined by high
performance liquid chromatography (HPLC), was found to be >97%.
Sulfamethoxazole, dapsone, epiandrosterone (EPI), NADP, glucose
6-phosphate, 1-chloro-2,4-dinitrobenzene (CDNB), diethyl maleate (DEM),
3-amino-1,2,4-triazole (AT), HEPES, DMSO, and purified human hemoglobin
A0 (ferrous) were obtained from Sigma Chemical Co. (St.
Louis, MO). Methylene blue was obtained from Aldrich Chemical Co.
(Milwaukee, WI), and the remaining chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO), Fisher Scientific (Fair Lawn, NJ), and
J.T. Baker Chemical Co. (Phillipsburg, NJ). Solvents obtained from
Fisher Scientific (Fair Lawn, NJ) and Curtin Matheson Scientific
(Houston, TX) were of HPLC grade.
Study Subjects. Healthy human volunteers were recruited from the staff and students of the Department of Pharmaceutical Sciences at Wayne State University. Written informed consent was obtained from all volunteers before collecting 10 to 20 ml of whole blood into heparin-containing Vacutainer (Becton Dickinson; Rutherford, NJ) tubes. The study was approved by the Human Investigation Committee at Wayne State University.
Preparation of Intact RBCs and RBC Lysate. Human RBCs were isolated from heparinized whole blood by centrifuging samples at 2200g for 10 min at 4°C. After removal of the plasma and buffy coat layer, RBCs were washed once or twice with phosphate-buffered saline (PBS), pH 7.4. The final RBC pellet was then diluted with HEPES medium (15 mM HEPES, pH 7.4, 125 mM NaCl, 6 mM KCl, 1.2 mM MgSO4, 1 mM NaH2PO4, 1 mM CaCl2, 10 mM glucose) to yield a 35 to 50% hematocrit. RBC lysate was prepared by diluting isolated RBCs 1:1 with deionized water and then sonicating and vortexing samples to ensure complete cell lysis.
Methemoglobin Assay. DDS-NOH and SMX-NOH solutions were prepared in acetone to yield concentrations ranging from 1 µM to 20 mM. Then,75-µl aliquots were evaporated under a gentle stream of N2 and samples were cooled to 4°C. Isolated RBCs or RBC lysate was distributed to each tube (75 µl) on ice to ensure a synchronous start time, and incubations were continued for 1 h in a 37°C shaking water bath. The percent of total hemoglobin converted to methemoglobin (MetHgb) was then analyzed using 50 µl from each sample, as described below. All incubations used in generating pharmacodynamic data from intact cells or lysate of human volunteers were performed in triplicate. Incubations in the presence and absence of the various chemical agents described below were performed in duplicate.
Each sample (50 µl) was hemolyzed with 3.95 ml of deionized water and vortexed, and pH was maintained by adding 4 ml of PBS (pH 7.4). MetHgb levels, expressed as a percentage of total hemoglobin in each sample, were then determined according to the method of Fairbanks and Klee (1987)Equilibration of Parent Amines Across RBC Membranes.
Because
the instability of hydroxylamine metabolites prevents accurate
determination of their movement across biological membranes, equilibration of the parent arylamines was used as an indirect indicator of metabolite flux. RBCs were isolated as described above and
then diluted to 50% hematocrit with human plasma or PBS, pH 7.4. Concentrated aliquots of dapsone and sulfamethoxazole in DMSO (1%)
were added to yield 200 µM final concentrations. After mixing for 30 sec, samples were placed in a 37°C shaking water bath. At various
time points during a 1-h incubation period, 500-µl aliquots were
removed for analysis. RBCs were pelleted by centrifugation, and 200 µl of the supernatant was extracted with 3 ml of water-saturated
ethyl acetate. After discarding the remaining supernatant, RBCs were
lysed with deionized water, sonication, and vortexing, and 200 µl was
extracted as described above. The organic layers of all samples were
evaporated under a gentle stream of N2, and the residue was
reconstituted in either 200 µl or 100 µl mobile phase, so as to
account for sample dilution during the lysis procedure. HPLC analysis
was performed according to the method of Coleman et al. (1989)
. Data
was used to calculate ratios of intracellular (RBCs) to extracellular
arylamine concentration in each sample. Because steady-state
concentrations were observed within 5 min (data not shown), data shown
represent the mean ± S.D. of all time points during the 1-h
incubation period.
RBC-Mediated Formation of Parent Amines.
DDS-NOH and SMX-NOH
solutions were prepared in acetone, and 75-µl aliquots were added to
dry culture tubes and evaporated under a gentle stream of
N2. A 75-µl aliquot of RBCs (50% hematocrit) was added
to each tube on ice to ensure a synchronous start to all incubations.
After a brief 30-sec equilibration period at 37°C, incubations were
continued for 1 h in a shaking water bath and then terminated by
placing all samples on ice. RBCs were subsequently lysed with 125 µl
of deionized water, sonication, and vortexing and extracted with
water-saturated ethyl acetate, and parent amine formation was analyzed
by HPLC as described previously (Coleman et al., 1989
).
Effect of Glucose-6-phosphate Dehydrogenase Inhibition.
To
investigate the role of NADPH in the formation of MetHgb by
hydroxylamine metabolites, intact RBCs (50% hematocrit) were incubated
with 1 mM EPI for 1 h at 37°C. Crude analysis of
glucose-6-phosphate dehydrogenase (G6PD) activity, the enzyme
responsible for maintenance of intracellular NADPH levels, was
performed in the presence and absence of EPI as described previously
(Glock and McLean, 1953
). Concentration-MetHgb response relationships
were subsequently generated for both DDS-NOH and SMX-NOH after
pretreatment with 1 mM EPI or vehicle control (acetone, 0.5%).
Effect of Reduced Glutathione Depletion.
For experiments
aimed at investigating the effect of reduced glutathione (GSH)
depletion on hydroxylamine-induced MetHgb formation, GSH was depleted
using both CDNB and DEM. Initially, GSH depletion was accomplished by
incubating RBCs (50% hematocrit) with 5 mM CDNB for 1 h at 37°C
before continued incubation with SMX-NOH or DDS-NOH. Due to the
significant baseline level of MetHgb formed under these conditions
(~40%), however, incubation time with 5 mM CDNB was reduced to 15 min, followed by washing RBCs twice with PBS to remove all CDNB.
Subsequent results were confirmed by depleting GSH with 50 mM DEM for
1 h at 37°C. The extent of GSH depletion relative to vehicle
controls was determined by measuring GSH levels using an ion-exchange
HPLC assay described previously (Fariss and Reed, 1987
). For each
hydroxylamine, concentration-MetHgb response relationships were
generated in both normal and GSH-depleted RBCs.
Effect of Catalase Inhibition.
To examine whether production
of reactive oxygen species, particularly hydrogen peroxide, might play
some role in the differential MetHgb-forming potency of hydroxylamine
metabolites, human RBCs (35% hematocrit) were incubated with 50 mM AT
(dissolved in PBS) for 30 min at 37°C. Previous studies have
demonstrated that AT significantly inhibits catalase activity, even at
lower concentrations (Margoliash and Novogrodsky, 1958
; Margoliash et
al., 1960
). After incubation with or without AT, RBCs were exposed to
SMX-NOH or DDS-NOH, and MetHgb levels were analyzed as described above.
Effect of
N-[2-(2-oxo-1-Imidazolindinyl)-Ethyl]-N'-Phenylurea.
The heterocyclic compound
N-[2-(2-oxo-1-imidazolindinyl)-ethyl]-N'-phenylurea
(EDU) has previously been shown to increase the activity of superoxide
dismutase and catalase in lung, liver, and heart tissue (Stevens et
al., 1988
). EDU also significantly decreases the rate of hydroxyl
radical and superoxide anion production from a xanthine-xanthine
oxidase system with and without chelated iron, respectively, suggesting
that EDU might directly quench reactive oxygen species (Leanderson et
al., 1994
). Therefore, to further explore the potential role of
reactive oxygen species in hydroxylamine-induced MetHgb formation, RBCs
(50% hematocrit) were pretreated with 20 mM EDU or vehicle control
(1% DMSO) for 5 min at 37°C. Hydroxylamine-induced MetHgb formation
was then determined after 1 h as described above.
Effect of Stimulation of NADPH MetHgb Reductase with Methylene
Blue.
Previous studies failed to show an inhibitory effect of
DDS-NOH on NADH MetHgb reductase, quantitatively the most important MetHgb reducing enzyme in vivo (Kramer et al., 1972
). Whether hydroxylamines affect methylene blue-induced stimulation of NADPH MetHgb reductase activity is unknown. Therefore, RBCs (50% hematocrit) were incubated with or without 15 ng/ml methylene blue for 30 min in a
37°C shaking water bath. Subsequently, hydroxylamine-induced MetHgb
formation was assessed after an additional 1-h incubation at 37°C as
described above.
Effect of Hydroxylamines on Purified Hemoglobin. To compare the inherent reactivity of DDS-NOH and SMX-NOH, purified human hemoglobin A0 (ferrous) was suspended in PBS, pH 7.4, to yield a 50 mg/ml final concentration (corresponds, approximately, with a 15% hematocrit). After incubation with DDS-NOH or SMX-NOH, MetHgb formation was analyzed as described above. All incubations were performed in duplicate.
Statistical Analysis. Results are presented as mean ± S.D. where appropriate. Concentration-MetHgb response data from each subject were analyzed by fitting mean data for sample replicates to the Emax model (Table 1). Statistical significance was determined using either paired t-tests or one-way analysis of variance, with pairwise comparisons being performed according to the Student-Newman-Keuls method. P < .05 was considered statistically significant in every case.
|
| |
Results |
|---|
|
|
|---|
Comparison of MetHgb Formation and Conversion to Parent Amines. Comparison of the relative MetHgb-forming capacity of SMX-NOH and DDS-NOH revealed significant differences between these two hydroxylamine metabolites. Using washed human RBCs from four normal volunteers (all Caucasian men; age range, 24-42 years), a concentration-dependent increase in MetHgb formation was observed with both hydroxylamines (data not shown). EC50 and Emax values were generated for each subject by fitting data according to the Emax model (Table 1). A within-subjects pairwise comparison (Student-Newman-Keuls method) demonstrated a significant difference between EC50 values for SMX-NOH and DDS-NOH (P = 0.004) but not between Emax values. This difference in potency was maintained at all time points from 3 min to 23 h (data not shown). Thus, DDS-NOH is significantly more potent than but equally efficacious as SMX-NOH using intact RBCs.
Differences in the ability of hydroxylamines to cross RBC membranes would obviously affect their ability to induce MetHgb formation. Unfortunately, the instability of hydroxylamine metabolites in aqueous media prevented accurate experimental determination of their flux across biological membranes. Thus, we investigated the ability of the parent arylamines to equilibrate into RBCs as an indirect indicator of compound flux. Dapsone and sulfamethoxazole concentrations within RBCs and in the extracellular environment were analyzed by HPLC during 1 h. Regardless of whether RBCs were diluted with human plasma or PBS, dapsone concentrations within RBCs were significantly higher than intracellular sulfamethoxazole concentrations (Fig. 1; P < .05). RBC/PBS ratios indicate that unbound sulfamethoxazole equilibrates freely across RBC membranes, whereas dapsone becomes concentrated within RBCs.
|
|
|
Role of Redox Cycling in Hydroxylamine-Induced MetHgb
Formation.
Hydroxylamines are regenerated when nitroso species
produced during co-oxidation with hemoglobin react with NADPH (Kiese, 1966
; Kramer et al., 1972
) or GSH (Kramer et al., 1972
; Coleman et al.,
1994a
). We hypothesized that increased efficiency in the regeneration
of DDS-NOH might be a key component in its increased MetHgb-forming
potency. To test this hypothesis, we determined whether inhibition of
G6PD, which normally converts NADP+ to NADPH, has any
effect on hydroxylamine-induced MetHgb formation. Although significant
inhibition of G6PD activity was observed (>90%), only a very minor
rightward shift in the concentration-MetHgb response curves for both
DDS-NOH and SMX-NOH is apparent (Fig. 3).
Prevention of NADPH regeneration did not significantly affect the
MetHgb-forming potency of either hydroxylamine metabolite.
|
|
|
Investigation of Potential Role of Reactive Oxygen Species in
MetHgb Formation.
Although reactive oxygen species, including
hydroxyl radicals and hydrogen peroxide, are known to be produced
within RBCs exposed to hemotoxic agents, studies suggest varied
responses on exposure to similar chemical entities (Jollow et al.,
1995
). In light of the fact that hydrogen peroxide is a potent
MetHgb-forming agent, we hypothesized that differential production of
hydrogen peroxide or other reactive oxygen species may play some role
in the observed difference in MetHgb formation. To examine the possible role of hydrogen peroxide, human RBCs were pretreated with the catalase
inhibitor AT before incubation with DDS-NOH or SMX-NOH for 1 h. AT
has previously been shown to produce an immediate reversible inhibition
of catalase at high concentrations (Margoliash et al., 1960
) and a more
slowly developing irreversible inhibition in the presence of low
concentrations of hydrogen peroxide (Margoliash and Novogrodsky, 1958
).
The pretreatment of human RBCs with high concentrations of AT (50 mM
for 30 min) had no effect on the pharmacodynamics of
hydroxylamine-induced MetHgb formation (data not shown).
|
Effect of NADPH MetHgb Reductase Stimulation on MetHgb
Formation.
Inhibition of MetHgb reduction is likely to be
deleterious toward RBCs exposed to hemotoxic agents or those under
oxidant stress. Although one study failed to show an inhibitory effect of DDS-NOH on NADH-dependent MetHgb reductase (Kramer et al., 1972
), we
are unaware of previous studies investigating the potential effect of
hydroxylamines on the NADPH-dependent system, which can be stimulated
with methylene blue. To address this issue, human RBCs were pretreated
with or without methylene blue (15 ng/ml) before continued incubation
with DDS-NOH or SMX-NOH, respectively. As demonstrated in Fig.
6, hydroxylamine-induced MetHgb formation was significantly decreased in methylene blue-pretreated RBCs. Hydroxylamine concentration-MetHgb response curves are shifted to the
right of those pretreated with vehicle control (Fig. 6). This dampening
effect of methylene blue treatment, however, was no different in cells
that were subsequently exposed to DDS-NOH or SMX-NOH. Thus, neither
hydroxylamine demonstrated an inhibitory effect on stimulation of NADPH
MetHgb reductase activity.
|
Effect of Hydroxylamines on Purified Hemoglobin. Differences in RBC processing of hydroxylamines do not appear to account for the observed difference in potency between DDS-NOH and SMX-NOH. If this is indeed true, then DDS-NOH should display greater hemotoxicity than SMX-NOH in a cell-free system. To test this hypothesis, purified ferrous hemoglobin A0 was incubated with hydroxylamine metabolites for 1 h before determining the percent of hemoglobin converted to MetHgb. Despite their decreased potency in the absence of intact RBC or cell lysate, as demonstrated by the rightward shift of both concentration-MetHgb response curves, DDS-NOH still caused significantly greater levels of MetHgb formation than SMX-NOH (Fig. 7).
|
| |
Discussion |
|---|
|
|
|---|
Trimethoprim-sulfamethoxazole causes a high incidence of
hypersensitivity reactions that complicate its use for combating opportunistic infections in patients with AIDS (Gallant et al., 1994
;
Cribb et al., 1996a
). Dapsone causes fewer idiosyncratic reactions (Lee
et al., 1989
; Medina et al., 1990
) but is associated with frequent
dose-dependent hemotoxic effects (Lee et al., 1989
; Medina et al.,
1990
; Torres et al., 1993
; Beumont et al., 1996
). Although the
pathogenesis of these ADRs remains unclear, evidence suggests that
bioactivation to reactive hydroxylamine metabolites occurs before the
manifestation of adverse effects. Despite similar metabolic fates,
however, differences in the incidence of ADRs suggest that important
differences in the production, disposition, detoxification, and/or
reactivity of hydroxylamine metabolites derived from these substrates
may occur in vivo. These studies were designed to better evaluate the
role of RBCs in modulating the disposition and toxicity of
hydroxylamine metabolites of sulfamethoxazole and dapsone.
Using a three-compartment dialysis system, Tingle and Park (1993)
demonstrated that human RBCs protect mononuclear leukocytes against
DDS-NOH-induced cytotoxicity. Interestingly, this does not appear to be
a universal phenomenon because RBCs failed to protect against reactive
metabolites of procainamide, hydralazine, and primaquine (Tingle and
Park, 1993
). Recent work in our laboratory comparing the relative
cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and
dapsone suggested that RBCs could ameliorate the cytotoxicity of
SMX-NOH and MADDS-NOH (Reilly et al., 1998
). Because RBC-mediated
detoxification of reactive metabolites appears to correlate with MetHgb
formation (Coleman and Jacobus, 1993
; Tingle and Park, 1993
), we
evaluated the pharmacodynamics of DDS-NOH- and SMX-NOH-induced MetHgb
formation in human RBCs.
A comparison of MetHgb-forming ability using intact RBCs suggested that
DDS-NOH was significantly more potent than SMX-NOH (Table 1). However,
because hydroxylamine metabolites are believed to react with hemoglobin
and O2 in a simple coupled oxidation reaction
that produces MetHgb (Kiese, 1966
), this difference in hemotoxic
potency was initially attributed to a potential difference in the entry
of DDS-NOH and SMX-NOH into cells. Using sulfamethoxazole and dapsone
movement across RBC membranes as an indirect indicator of hydroxylamine
flux, dapsone was shown to significantly concentrate within RBCs (Fig.
1). In contrast, sulfamethoxazole concentrations were nearly identical
in the intracellular and extracellular compartments, suggesting that
unbound sulfamethoxazole freely diffuses across RBC membranes. If
hydroxylamine metabolites behave similarly, differences in distribution
could significantly affect the MetHgb-forming potency of DDS-NOH and
SMX-NOH. Removal of the membrane barrier by lysing of the RBCs,
however, did not negate the difference in potency.
EC50 values for DDS-NOH remained approximately
20-fold lower than EC50 values for SMX-NOH (Table
2), suggesting a potency difference unrelated to RBC distribution.
Surprisingly, the equilibrium level of MetHgb formation in lysate was
not lower, as had been reported previously (Kramer et al., 1972
).
Although hemolysis should disrupt the erythrocytic recycling of
hydroxylamines (Coleman et al., 1996
), we hypothesize that the limited
dilution of intracellular contents (50%) produced by our lysis
procedure maintained sufficient concentrations of reducing species to
allow continued recycling. This is supported by Coleman et al. (1996)
,
who reported comparable levels of GSH in lysate and intact RBCs.
Differences in the cellular distribution of hydroxylamines may still
contribute to the differential incidence of dapsone- and
sulfamethoxazole-induced adverse effects. Sequestration of DDS-NOH and
MADDS-NOH by human RBCs in vivo, which would increase the intracellular
concentration of reactive species, might explain why dapsone is
associated with significant hemotoxic effects. These data also support
the suggestion that RBCs serve as a conduit delivering DDS-NOH and
MADDS-NOH to bone marrow, where they may bind granulocyte precursors
and cause agranulocytosis (Coleman, 1995
). Moreover, RBC-mediated
sequestration of DDS-NOH may contribute to the lower incidence of
dapsone-induced hypersensitivity reactions if local, rather than
systemic, concentrations of hydroxylamine are critical in initiating
the cascade of events that lead to an idiosyncratic response.
To explain the persistently lower MetHgb-forming potency of SMX-NOH, we
subsequently hypothesized that differences in RBC processing may be a
contributing factor. As depicted in Fig.
8, hydroxylamines co-oxidize with
hemoglobin to produce reactive nitroso metabolites and reactive oxygen
intermediates. Previous work demonstrated that the nitroso may either
recycle back to the hydroxylamine by reaction with NADPH (Kiese, 1966
;
Kramer et al., 1972
) or GSH (Kramer et al., 1972
; Coleman et al.,
1994a
) or be detoxified in a GSH-dependent mechanism that yields the parent arylamine (Cribb et al., 1991
; Coleman and Jacobus, 1993
). Increased efficiency in the regeneration of DDS-NOH would increase MetHgb formation, whereas increased shunting of the nitroso product of
sulfamethoxazole toward the detoxifying pathway would decrease the
MetHgb potency of SMX-NOH. Our results support the role of GSH, not
NADPH, as the key reducing species responsible for regenerating hydroxylamine metabolites. As has been observed previously,
hydroxylamines did not significantly deplete GSH from human RBCs
(Table 3) (Kramer et al., 1972
; Glader and Conrad, 1973
; Scott and
Rasbridge, 1973
). Any GSH that was consumed in the recycling of
hydroxylamines must have been rapidly regenerated. The minor shift in
the concentration-MetHgb response curves caused by inhibition of G6PD
(Fig. 3) is, therefore, believed to result from the secondary
requirement of NADPH for regeneration of GSH. Interestingly,
hydroxylamines have been shown to significantly deplete GSH from
rat RBCs (Grossman et al., 1992
, 1995
), which may account for the
species difference in sensitivity to hydroxylamine-induced MetHgb
formation (Vage et al., 1994
; Tingle et al., 1997
). The inability of
rat RBCs to maintain GSH levels would decrease their ability to
efficiently recycle nitroso derivatives back to the hydroxylamine.
Although depletion of GSH levels did decrease the MetHgb-forming
capacity of DDS-NOH and SMX-NOH, presumably by eliminating the
recycling process, it did not eliminate the relative difference in
potency (Fig. 4). The lack of difference in cycling efficiency
therefore precludes this as a contributing factor toward the difference
in potency.
|
Some differences were observed, however, in the conversion
of hydroxylamine metabolites to their parent arylamines. At
concentrations of DDS-NOH reportedly achieved in vivo (Grossman and
Jollow, 1988
), substantially greater amounts of dapsone were formed by
RBCs (Fig. 2). Again, these data cannot account for the greater
MetHgb-forming potency of DDS-NOH, but they might contribute somewhat
to the differential incidence of drug-induced hypersensitivity
reactions. If under physiologic conditions, an RBC-mediated,
GSH-dependent reductive pathway detoxifies more of the reactive
metabolites of dapsone, less hydroxylamine would be present to initiate
dapsone-induced hypersensitivity reactions.
Indirect evidence also suggested that a free radical mechanism
involving hydroxyl radicals and hydrogen peroxide may contribute to
MetHgb formation (Kiese, 1966
). Reactive oxygen species are produced
when hydroxylamines react with hemoglobin in the presence of
O2 (Kiese, 1966
), although the formation of free
radicals may differ with the hydroxylamine metabolite under
consideration (Jollow et al., 1995
). To investigate whether these
differences might contribute to the differential formation of MetHgb,
various agents were used to manipulate RBC antioxidant enzyme systems.
If reactive oxygen species did play a role, recent studies suggested
that catalase should be more important than glutathione peroxidase in
protecting RBCs from oxidative stress (Scott et al., 1991a
, b
; Gaetani
et al., 1996
). However, in our experimental system, pretreatment with
the catalase inhibitor AT had no effect on
hydroxylamine-induced MetHgb formation. Moreover, although NADPH
has been shown to be required as a cofactor for reactivation of
catalase complex II (Kirkman and Gaetani, 1984
), inhibition of G6PD,
which prevents regeneration of NADPH levels, also had no significant
effect on MetHgb formation (Fig. 3). Together with previous evidence
demonstrating that AT had no effect on DDS-NOH-induced hemolytic anemia
(Grossman et al., 1995
), our data suggest that catalase does not
protect against the hemotoxic effects of DDS-NOH.
To further probe the potential involvement of reactive oxygen
intermediates, we also questioned whether stimulation of antioxidant activity might decrease the observed MetHgb formation. The heterocyclic compound EDU, which has been shown to possess several antioxidant properties (see Materials and Methods) (Stevens et al.,
1988
; Leanderson et al., 1994
), had no effect (Fig. 5). Collectively, these data strongly suggest that reactive oxygen species do not play a
role in hydroxylamine-induced MetHgb formation. Reactive oxygen species
generated during MetHgb formation may instead play a critical role in
the development of hemolytic anemia (Rasbridge and Scott, 1973
; Scott
and Rasbridge, 1973
; Jollow et al., 1995
), although further comment is
beyond the scope of this discussion.
The observed difference in MetHgb-forming potency might also occur if
hydroxylamines differentially affect the MetHgb reductase activity that
combats oxidative stress and hemotoxic agents (see Fig. 8). Inhibition
of the NADH-dependent system that predominates under normal conditions
or the NADPH-dependent system stimulated under conditions of oxidative
stress might significantly increase MetHgb formation. Our data provide
indirect evidence that DDS-NOH and SMX-NOH do not affect stimulation of
NADPH-dependent reductase activity with methylene blue (Fig. 6).
Together with previous evidence showing that DDS-NOH did not inhibit
the NADH-dependent system (Kramer et al., 1972
), these data indicate
that alterations in MetHgb reductase activity also cannot account for
the differences in MetHgb-forming potency.
The inherent reactivity of each metabolite was assessed using a cell-free system. The increased conversion of purified hemoglobin A0 to MetHgb (Fig. 7) suggests that DDS-NOH is inherently more reactive with heme constituents of hemoglobin than is SMX-NOH. The structural basis for this difference in potency remains to be determined.
In summary, our results provide evidence suggesting that the high incidence of dapsone-induced hemotoxicity may be linked to the ability of RBCs to sequester dapsone and its reactive species and the inherently greater reactivity of its hydroxylamine metabolites with hemoglobin. If sulfamethoxazole- and dapsone-induced hypersensitivity reactions are also related to the action of hydroxylamine metabolites, preferential sequestration of DDS-NOH and increased detoxification to the parent dapsone may contribute to the lower incidence of idiosyncratic reactions caused by dapsone.
| |
Acknowledgments |
|---|
We thank Dr. Frank H. Bellevue III (Department of Chemistry, Manhattanville College, Purchase, NY) for his assistance in synthesizing SMX-NOH and Dr. Lawrence H. Lash and David Putt (Department of Pharmacology, Wayne State University, Detroit, MI) for determining RBC GSH levels. The generous contribution of EDU by Dr. David J. Bassett (Department of Occupational and Environmental Health Sciences, Wayne State University, Detroit, MI) and Dr. Janet Kerr (DuPont Pharmaceutical, Wilmington, DE) also is greatly appreciated.
| |
Footnotes |
|---|
Accepted for publication September 29, 1998.
Received for publication June 24, 1998.
1 This work was supported in part by National Institutes of Health Grant AI41395 (to C.K.S.). Portions of this work were presented at Experimental Biology '98 in San Francisco, CA, April 20, 1998. T.P.R. was the recipient of an Advanced Predoctoral Fellowship in Pharmacology/Toxicology from the Pharmaceutical Researchers and Manufacturers of America Foundation (Washington, DC).
Send reprint requests to: Craig K. Svensson, Pharm.D., Ph.D., Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202. E-mail: cks{at}wizard.pharm.wayne.edu
| |
Abbreviations |
|---|
ADR, adverse drug reactions; AT, 3-amino-1,2,4-triazole; CDNB, 1-chloro-2,4-dinitrobenzene; DDS-NOH, dapsone hydroxylamine; DEM, diethyl maleate; EDU, N-[2-(2-oxo-1-imidazolindinyl)-ethyl]-N'-phenylurea; Emax, maximum methemoglobin response (expressed as percent of hemoglobin present as MetHgb); EC50, concentration causing 50% Emax; EPI, epiandrosterone; G6PD, glucose-6-phosphate dehydrogenase; GSH, reduced glutathione; HPLC, high-performance liquid chromatography; MADDS-NOH, monoacetyldapsone hydroxylamine; MetHgb, methemoglobin; PBS, phosphate-buffered saline; RBC, red blood cell; SMX-NOH, sulfamethoxazole hydroxylamine.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Roychowdhury, P. M. Vyas, T. P. Reilly, A. A. Gaspari, and C. K. Svensson Characterization of the Formation and Localization of Sulfamethoxazole and Dapsone-Associated Drug-Protein Adducts in Human Epidermal Keratinocytes J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 43 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Reilly, R. D. MacArthur, M. J. Farrough, L. R. Crane, P. M. Woster, and C. K. Svensson Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals? J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1356 - 1364. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||